Market: NASD |
Currency: USD
Address: 6801 N. Capital of Texas Highway
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
📈 Cassava Sciences, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-13
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2017 |
- |
$0.142857 |
- |
2017-05-10 |
- |
Stock split |
|
Total Amount for 2017: $0.142857 |
📅 Earnings & EPS History for Cassava Sciences, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-03-03 | -0.57 |
| 2024-11-07 | -0.58 |
| 2024-08-08 | -1.28 |
| 2024-05-10 | -0.43 |
| 2024-02-28 | -0.5 |
| 2023-11-07 | -0.61 |
| 2023-08-03 | -0.63 |
| 2023-05-01 | -0.58 |
| 2023-02-28 | -0.47 |
| 2022-11-07 | -0.51 |
| 2022-08-04 | -0.48 |
| 2022-05-05 | -0.44 |
| 2022-02-28 | -0.35 |
| 2021-11-10 | -0.24 |
| 2021-08-03 | -0.13 |
| 2021-04-21 | -0.09 |
| 2021-03-23 | -0.09 |
| 2020-11-09 | -0.06 |
| 2020-08-12 | -0.05 |
| 2020-03-26 | -0.09 |
| 2019-10-29 | -0.04 |
| 2019-08-12 | -0.06 |
| 2014-02-04 | 5.04 |
| 2013-10-31 | -0.14 |
📰 Related News & Research
No related articles found for "cassava sciences".
